IL2 and non-small cell lung carcinoma: showed in an in vitro study of NSCLC that the efficacy of nivolumab in restoring T‐cell effector function (as measured by expression of cytokines IL‐2, IFNγ, and TNFα) was inversely correlated with the percentage of high PD‐1‐expressing T cells 70.